Vaxcyte Inc. (PCVX) News
Filter PCVX News Items
PCVX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PCVX News Highlights
- For PCVX, its 30 day story count is now at 2.
- Over the past 13 days, the trend for PCVX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest PCVX News From Around the Web
Below are the latest news stories about VAXCYTE INC that investors may wish to consider to help them evaluate PCVX as an investment opportunity.
Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Disposes of 8,000 SharesVaxcyte Inc (NASDAQ:PCVX), a company specializing in vaccine innovation with a focus on improving global health through the development of superior vaccines, has reported an insider selling event. |
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) at all Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2 mcg PCV Dose Met or Exceeded Regulatory Immunogenicity Standards -- -- Results Confirm Potential of Carrier-Sparing, Cell-Free Platform Technology Underlying VAX-24 -- -- Topline Data from the VAX-24 Phase 3 Pivotal Non-Inferiority Study in Adults Expected in 2025 -- SAN CARLOS, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Va |
Vaxcyte Appoints Jacks Lee to Board of DirectorsSAN CARLOS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Jacks Lee to its Board of Directors. “We are pleased to welcome Jacks, an accomplished industry leader with extensive biopharmaceutical and vaccine manufacturing, supply and operations expertise, to Vaxcyte’s Board of Directors as we continue to reali |
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Rights Agreement Further Strengthens Vaxcyte’s Long-Term, Global Commercial Manufacturing Strategy as Lead PCV Candidate, VAX-24, Advances into Phase 3 -- SAN CARLOS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Vaxcyte) (NASDAQ: PCVX) and Sutro Biopharma, Inc |
Insider Sell Alert: Vaxcyte Inc's President and CFO Andrew Guggenhime Sells 8,000 SharesIn the realm of stock market movements, insider trading activity is often a significant indicator that investors keep a close eye on. |
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults-- VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline Safety, Tolerability and Immunogenicity Data Expected in Second Half of 2024 -- -- VAX-31 is Designed to Provide Coverage for Approximately 95% of Invasive Pneumococcal Disease Circulating in the U.S. Adult Population -- SAN CARLOS, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccin |
Vaxcyte Inc (PCVX) Reports Q3 2023 Financial Results and Business UpdatesCompany's Cash Position Strengthens to $1.4 Billion, R&D Expenses Increase Due to Manufacturing Expenses and Personnel-Related Costs |
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update-- Completed Successful End-of-Phase 2 Meeting with FDA for VAX-24; Topline Phase 3 Data in Adults Expected in 2025 -- -- Received FDA Clearance of VAX-31 Adult IND Application; Phase 1/2 Study Initiation Expected This Quarter and Topline Data Expected in the Second Half of 2024 -- -- Advanced Ongoing VAX-24 Infant Phase 2 Study; Topline Data from Primary Immunization Series Expected by 2025 -- -- Expanded Collaboration with Lonza for Global Commercial Manufacturing of Broad-Spectrum Pneumococca |
Insider Sell: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX)On November 1, 2023, Jim Wassil, the Chief Operating Officer (COO) of Vaxcyte Inc (NASDAQ:PCVX), sold 3,000 shares of the company. |